Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$136.46 USD
+0.65 (0.48%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $136.61 +0.15 (0.11%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ASND 136.46 +0.65(0.48%)
Will ASND be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ASND
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
Other News for ASND
Ascendis Pharma Outlines Capital Strategy
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
Ascendant Resources Names New Auditor
Ascendant Appoints McGovern Hurley As Company Auditor
TimesSquare Capital Global Small Cap Q1 2024 Commentary